Literature DB >> 526395

Labetalol in severe and resistant hypertension.

L C Williams, M J Murphy, V Parsons.   

Abstract

1 The efficacy of labetalol in the treatment of severe hypertension (diastolic greater than or equal to 115 mm Hg) was studied retrospectively. Ten patients were followed for more than 6 months. At 6 months, eight were well controlled and the mean dose in those was 975 mg daily. Four of these were receiving labetalol alone; two were on labetalol and diuretic only. 2 Three patients were resistant to doses of 1600, 1800 and 2400 mg daily respectively; two of these were controlled with increased doses of vasodilator drugs. In two cases labetalol had produced large falls in the standing BP while not influencing the supine BP. 3 Three other resistant patients were seen, of whom one merely required an increase in dose to 2200 mg daily and the addition of a diuretic. Both the others were elderly, had severe vascular disease, and suffered disabling postural hypotension on a dose of labetalol which did not influence the supine BP. 4 Labetalol can control severe hypertension. There remain patients whose supine BP is not influenced by a dose of labetalol which produces marked postural hypotension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526395      PMCID: PMC1429737     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

2.  Labetalol in the treatment of patients with hypertension and renal function impairment.

Authors:  R R Bailey
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension.

Authors:  G G Geyskes; P Boer; J Vos; F H Leenen; E J Mees
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

4.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

5.  Different antihypertensive effect of beta-blocking drugs in low and normal-high renin hypertension.

Authors:  B E Kralberg; K Tolagen
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

6.  Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker).

Authors:  J Menard; X Bertagna; P T N'Guyen; P Degoulet; P Corvol
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

7.  Controlled comparison of labetalol and propranolol in the management of severe hypertension.

Authors:  D J Pugsley; B K Armstrong; M A Nassim; L J Beilin
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

8.  Labetalol in resistant hypertension.

Authors:  H J Dargie; C T Dollery; J Daniel
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Renin reactivity as a determinant of responsiveness to antihypertensive treatment.

Authors:  M A Weber; J A Lopez-Ovejero; J I Drayer; D B Case; J H Laragh
Journal:  Arch Intern Med       Date:  1977-03

10.  Beta-blockers and plasma renin activity in hypertension.

Authors:  G S Stokes; M A Weber; I R Thornell
Journal:  Br Med J       Date:  1974-01-12
View more
  3 in total

1.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.

Authors:  G R Bellamy; S N Hunyor; D Roffe; J Massang
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

Review 3.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.